Replimune Group Stock Short Interest Rises to 43.93%

Replimune Group short interest was 43.93% of the float on April 15th, according to new data we received from Benzinga. Short interest totaled 18,426,035 shares, which was an increase of 12.8% from March 31st.

It is estimated that it would take 1.39 days for short sellers to buy back their shares, with current trading volumes.

Replimune Group Hedge Fund Activity

We have seen 97 institutional investors add shares of Replimune Group stock to their portfolio, and 82 decrease their positions in their most recent quarter.

Here are some of the largest recent moves:

• RTW INVESTMENTS, LP added 5,075,342 shares (+245.8%) to their portfolio in Q4 2025, for an estimated $49,332,324
• POINT72 ASSET MANAGEMENT, L.P. removed 3,557,692 shares (-98.0%) from their portfolio in Q4 2025, for an estimated $34,580,766
• TANG CAPITAL MANAGEMENT LLC removed 3,400,000 shares (-100.0%) from their portfolio in Q4 2025, for an estimated $33,048,000
• BRAIDWELL LP removed 2,750,092 shares (-100.0%) from their portfolio in Q4 2025, for an estimated $26,730,894
• READYSTATE ASSET MANAGEMENT LP removed 2,621,012 shares (-100.0%) from their portfolio in Q4 2025, for an estimated $25,476,236
• BALYASNY ASSET MANAGEMENT L.P. removed 2,602,781 shares (-99.0%) from their portfolio in Q4 2025, for an estimated $25,299,031
• D. E. SHAW & CO., INC. added 2,171,547 shares (+538.2%) to their portfolio in Q4 2025, for an estimated $21,107,436

To track hedge funds’ stock portfolios, check out Quiver Quantitative’s institutional holdings dashboard. You can access data on hedge funds moves and 13F filings through the Quiver Quantitative API.

Replimune Group Insider Trading Activity

Replimune Group insiders have traded $REPL stock on the open market 5 times in the past 6 months. Of those trades, 0 have been purchases and 5 have been sales.

Here’s a breakdown of recent trading of $REPL stock by insiders over the last 6 months:

• SUSHIL PATEL (Chief Executive Officer) sold 10,000 shares for an estimated $111,300
• CHRISTOPHER SARCHI (Chief Commercial Officer) has made 0 purchases and 2 sales selling 11,708 shares for an estimated $99,457.
• KONSTANTINOS XYNOS (Chief Medical Officer) sold 7,248 shares for an estimated $65,956
• KAPIL DHINGRA sold 3,169 shares for an estimated $32,957

To track insider transactions, check out Quiver Quantitative’s insider trading dashboard. You can access data on insider stock transactions through the Quiver Quantitative API.

Replimune Group Analyst Ratings

Wall Street analysts have issued reports on $REPL in the last several months. We have seen 0 firms issue buy ratings on the stock, and 2 firms issue sell ratings.

Here are some recent analyst ratings:

• JP Morgan issued a “Underweight” rating on 04/13/2026
• HC Wainwright & Co. issued a “Sell” rating on 04/13/2026

To track analyst ratings and price targets for Replimune Group, check out Quiver Quantitative’s $REPL forecast page.

Replimune Group Price Targets

Multiple analysts have issued price targets for $REPL recently. We have seen 5 analysts offer price targets for $REPL in the last 6 months, with a median target of $2.0.

Here are some recent targets:

• Roger Song from Jefferies set a target price of $2.0 on 04/13/2026
• Jonathan Chang from Leerink Partners set a target price of $2.0 on 04/13/2026
• Robert Driscoll from Wedbush set a target price of $2.0 on 04/13/2026
• Allison Bratzel from Piper Sandler set a target price of $14.0 on 02/05/2026
• Evan David Seigerman from BMO Capital set a target price of $11.0 on 11/03/2025

This article is not financial advice. See Quiver Quantitative’s disclaimers for more information. Note that there may be inaccuracies due to mistakes in ticker-mapping, and other anomalies.

Check out the Quiver Quantitative API to build on top of data on congressional stock trading, insider transactions, hedge fund moves, and more.